Mycoplasma vaccine composition and methods
AssigneeUniversity of Connecticut
InventorsSteven M. Szczepanek, Steven J. Geary, Edan R. Tulman
Life of this patent
Estimating the term…
Abstract
Described are vaccine compositions, methods of manufacture thereof, and methods of treating or preventing certain bacterial infections in humans and other mammals. For example, described are compositions comprising bacterial cell extracts that have undergone pretreatment such that lipid moieties have been cleaved from bacterial lipoproteins, thereby forming a vaccine composition that can stimulate a desired mammalian immune response while avoiding unwanted negative effects.
Claims12
A vaccine composition comprising a de-lipidated or non-lipidated mollicute bacteria material, wherein the de-lipidated or non-lipidated bacteria material includes at least one of:
- a reduced amount of lipid moieties bound to membrane-associated lipoproteins relative to wildtype or untreated mollicute bacteria material;
- a reduced amount of membrane-associated lipoproteins relative to wildtype or untreated mollicute bacteria material;
- or
- a combination thereof,
- wherein the mollicute bacteria material is derived from any bacteria of the genus Mycoplasma or the genus Ureaplasma.
Dependencies are inferred from the claim text.